Patient characteristics at baseline
| Characteristic . | Value . |
|---|---|
| N | 20 |
| Age, y | 67 (42-86) |
| Male sex, n (%) | 15 (75) |
| White blood cell count, ×109/L | 13.63 (1.14-210.6) |
| Absolute lymphocyte count, ×109/L | 8.33 (0.37-201.6) |
| Absolute neutrophil count, ×109/L | 2.91 (0.63-8.00) |
| Hemoglobin, g/L | 11.7 (7.6-14.8) |
| Platelet count, ×109/L | 119 (49-474) |
| Spleen size, cm | 22.5 (15.5-36) |
| Circulating HCLv cells, ×106/L | 5,877 (4.14-241 000) |
| Bone marrow HCLv cells, % | 35 (5-90) |
| IGHV4-34 unmutated IgH, n (%) | 7 (37) |
| Time from diagnosis to treatment, mo | 12.4 (1.9-147.7) |
| Prior treatment | |
| Untreated | 8 |
| Cladribine monotherapy | 6 |
| Cladribine, rituximab, splenectomy | 1 |
| Cladribine, splenectomy | 1 |
| R-CVP, cladribine | 1 |
| Rituximab, splenectomy | 1 |
| Rituximab monotherapy | 1 |
| Splenectomy | 1 |
| Time from prior treatment, mo | 14.5 (3.5-53.7) |
| Characteristic . | Value . |
|---|---|
| N | 20 |
| Age, y | 67 (42-86) |
| Male sex, n (%) | 15 (75) |
| White blood cell count, ×109/L | 13.63 (1.14-210.6) |
| Absolute lymphocyte count, ×109/L | 8.33 (0.37-201.6) |
| Absolute neutrophil count, ×109/L | 2.91 (0.63-8.00) |
| Hemoglobin, g/L | 11.7 (7.6-14.8) |
| Platelet count, ×109/L | 119 (49-474) |
| Spleen size, cm | 22.5 (15.5-36) |
| Circulating HCLv cells, ×106/L | 5,877 (4.14-241 000) |
| Bone marrow HCLv cells, % | 35 (5-90) |
| IGHV4-34 unmutated IgH, n (%) | 7 (37) |
| Time from diagnosis to treatment, mo | 12.4 (1.9-147.7) |
| Prior treatment | |
| Untreated | 8 |
| Cladribine monotherapy | 6 |
| Cladribine, rituximab, splenectomy | 1 |
| Cladribine, splenectomy | 1 |
| R-CVP, cladribine | 1 |
| Rituximab, splenectomy | 1 |
| Rituximab monotherapy | 1 |
| Splenectomy | 1 |
| Time from prior treatment, mo | 14.5 (3.5-53.7) |
Data are presented as median (range) unless otherwise indicated. IgH, immunoglobulin heavy chain rearrangement; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisone.